Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14685783 | 0.90 | GLP1R (0.54) | GLP1RMEN1KMT2AFOLH1RECQL | |
| SCHEMBL16493149 | 0.88 | GLP1R (0.49) | GLP1RFOLH1RECQLTLR2TSHR | |
| SCHEMBL21172251 | 0.87 | GLP1R (0.62) | GLP1RMEN1KMT2AFOLH1 | |
| SCHEMBL19286771 | 0.85 | GLP1R (0.57) | GLP1RMEN1KMT2AFOLH1 | |
| SCHEMBL24198474 | 0.85 | GLP1R (0.48) | GLP1RMEN1KMT2ARECQLTSHR | |
| SCHEMBL14683533 | 0.85 | GLP1R (0.48) | GLP1RMEN1KMT2ARECQLTSHR | |
| SCHEMBL19069582 | 0.84 | GLP1R (0.56) | GLP1RFOLH1 | |
| SCHEMBL19153350 | 0.84 | GLP1R (0.56) | GLP1RFOLH1 | |
| SCHEMBL24470266 | 0.84 | GLP1R (0.48) | GLP1RMEN1KMT2ARECQL | |
| SCHEMBL15871519 | 0.83 | GLP1R (0.56) | GLP1RMEN1KMT2AFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895694-B2 | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK A/S (DK) | 2014-11-25 | — | — | US | disclosed |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | GLP1R 1/4885MEN1 2368/4885KMT2A 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.